I think it's a fair assumption that the patients in the IV trial will on average be sicker than in the previous oral trial. It's quite common for people to die of pneumonia while in the hospital. What happens to CEMP's share price if for example 7 people taking Moxi die and only 2 people taking Soli die? Also assume that the rest of the outcomes are on the whole at least somewhat superior for Soli vs. Moxi.
True, but at some time before 7/15/15 the advisory committee will *advise* the FDA. Generally that advice is publicized and I was wondering when it would be publicized
An FDA Advisory Committee will be reviewing Praluent on June 9th. This hearing is open to the public so I imagine we'll get some sort of news out of it. Does anyone have an opinion as to how long afterwards it will take this advisory committee to render an opinion to the FDA?
I hate to break it to you but it was up just this past week. You can now go back to making stuff up:)
You beat me to it. I was just getting ready to check the clinical trials site as well, so yeah, 860 should be the correct number. I'm guessing if enrollment is complete in July we'll get results in October.
Today's press release said they had enrolled 610 patients on the IV trial so far. It took a little digging but a December 2013 press release said the total enrollment would be around 800. Not far to go!!!
Also let's not forget that the total milestone potential on the Japan deal is 60 million. Plus that deal was signed
almost a year ago. Toyama was smart to be an early believer. Soli has been substantially de-risked since then. Any future partners who now show up this late in the game will have to pay a large premium for their tardyness.
Probably theypre just extrapolating from what Cempra executives have already said. Which is that Cempra might pursue a split strategy of going it alone in the hospital setting and getting a partner for the community setting. The hospital setting would require a smaller salesforce than the community setting.
If McDonalds had any sense they would buy them out and ramp up the store rollout. I'm sure they regret in a big way spinning out Chipotle. This would be their chance to get back in the game.... assuming of course they didn't muck things up. As nice as a quick hit from a buyout is however, a multi-year multi-bagger is even nicer though. It takes a little more patience though.
Go to clinicaltrialsdotgov and type in solithromycin. 8 clinical trials will show up. The Soli iv trial is number 6
This may have something to do with today's gain. The clinical trials site has been listing a July 2015 completion date for the Soli IV trial. That is unchanged. However the site is listing April 7 2015 as the "last updated" and "verified dates". Previously those 2 dates were January 2015 dates. So in other words the trial completion is right on target to be completed this July. Personally I was hoping the date might be bumped up a month or two earlier but July will be here before you know it!
Or maybe CEMP is just catching up after some understandable profit taking.
Thank you so much for contributing to the discussion. Your imput was monumentally helpful :P
Actually I take plenty of stock market risk but for some odd reason never could bring myself to buy EW (til now) even though in retrospect it was a proven story and I had lots of opportunity to do so at lower prices. Anyhow that is now remedied. Truly great companies can remain good buys for many years, even after big initial gains and I feel EW has a lot of runway left.
Other picks: CEMP, CBM, PiNC, iCAD, CRL, iRiX, iCLR, FRSH, LOCO, TFX.
As for utilities I don't own any. Adjusted for inflation, buying low growth stocks can be the biggest risk of all. Especially when interest rates pretty much have only one direction to go from here.